Commercial Lilly and Novo face off at ADA 2026 as others seek to compete in obesity BioSpaceThe American Diabetes Association's annual congress will feature a superstar lineup, including weight loss giants Eli Lilly and Novo Nordisk.Metabolic & GLP-1Read full story pharminent June 5, 2026 (Last updated: June 5, 2026) BioSpace The American Diabetes Association’s annual congress will feature a superstar lineup, including weight loss giants Eli Lilly and Novo Nordisk. Metabolic & GLP-1 Read full story Post navigation Previous: Medicare Advantage in 2026: Premiums, Out-of-Pocket Limits, Supplemental Benefits, and Prior AuthorizationNext: Roche doubles down on BTK with $2.3bn Nurix deal Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026